Biswas et al. [1] also strongly suggested pharmacogenetic assessments through molecular docking or computational approaches for drug–gene pairs of ivermectin-ABCB1 to achieve precision medicines in COVID-19 patients. This evidence concerns the gene ABCB1 and COVID-19.